Rep. Nancy Pelosi Purchases Shares of Tempus AI, Inc. (NASDAQ:TEM)

Representative Nancy Pelosi (D-California) recently bought shares of Tempus AI, Inc. (NASDAQ:TEM). In a filing disclosed on January 23rd, the Representative disclosed that they had bought between $50,001 and $100,000 in Tempus AI stock on January 16th.

Representative Nancy Pelosi also recently made the following trade(s):

• Purchased $250,001 – $500,000 in shares of NVIDIA (NASDAQ:NVDA) on 1/16/2026.
• Purchased $500,001 – $1,000,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/16/2026.
• Purchased $500,001 – $1,000,000 in shares of Alphabet (NASDAQ:GOOGL) on 1/16/2026.
• Purchased $100,001 – $250,000 in shares of Vistra (NYSE:VST) on 1/16/2026.
• Sold $5,000,001 – $25,000,000 in shares of Apple (NASDAQ:AAPL) on 12/30/2025.
• Sold $1,000,001 – $5,000,000 in shares of Walt Disney (NYSE:DIS) on 12/30/2025.
• Sold $250,001 – $500,000 in shares of PayPal (NASDAQ:PYPL) on 12/30/2025.
• Sold $1,000,001 – $5,000,000 in shares of Alphabet (NASDAQ:GOOGL) on 12/30/2025.
• Sold $5,000,001 – $25,000,000 in shares of Apple (NASDAQ:AAPL) on 12/24/2025.
• Sold $1,000,001 – $5,000,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/24/2025.

Tempus AI Price Performance

Tempus AI stock traded down $1.59 during trading hours on Friday, reaching $58.37. 7,883,470 shares of the stock were exchanged, compared to its average volume of 5,200,815. The stock has a 50 day moving average of $62.35 and a two-hundred day moving average of $73.39. The company has a market cap of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32.

Wall Street Analyst Weigh In

TEM has been the subject of several research analyst reports. HC Wainwright lowered their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Canaccord Genuity Group cut their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. JPMorgan Chase & Co. lowered their price objective on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Piper Sandler cut their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, BTIG Research upped their price target on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Eight equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI has an average rating of “Hold” and an average price target of $85.92.

Insiders Place Their Bets

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $58.87, for a total value of $9,787,137.50. Following the completion of the sale, the chief executive officer directly owned 8,908,283 shares of the company’s stock, valued at $524,430,620.21. The trade was a 1.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the transaction, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 775,159 shares of company stock valued at $50,789,800. 26.27% of the stock is currently owned by corporate insiders.

Institutional Trading of Tempus AI

Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. increased its holdings in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares in the last quarter. Global Retirement Partners LLC grew its position in shares of Tempus AI by 29.5% during the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after buying an additional 167 shares during the period. US Bancorp DE increased its stake in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after acquiring an additional 176 shares in the last quarter. Legacy Bridge LLC lifted its position in shares of Tempus AI by 1.6% during the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after acquiring an additional 193 shares during the period. Finally, Truist Financial Corp boosted its stake in Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

About Representative Pelosi

Nancy Pelosi (Democratic Party) is a member of the U.S. House, representing California’s 11th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Pelosi (Democratic Party) is running for re-election to the U.S. House to represent California’s 11th Congressional District. She declared candidacy for the 2026 election.[source]

Pelosi is the first and only woman to serve as speaker of the House. Pelosi was first elected to the U.S. House in a special election in 1987 to represent California’s 5th Congressional District, which she represented until her election to California’s 8th Congressional District in 2012. In 2002, she was elected minority leader, becoming the highest-ranking congresswoman of either party in U.S. history. When Democrats took control of the House in 2007, Pelosi made history again with her election as speaker of the House.

Pelosi was re-elected speaker of the House in 2019, following the 2018 midterm elections. She served in that role until January 3, 2023.

Notable legislation passed during her speakership includes the Affordable Care Act, the American Recovery and Reinvestment Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Lilly Ledbetter Fair Pay Act, and the Don’t Ask, Don’t Tell Repeal Act.

Pelosi is also a prominent Democratic fundraiser, raising more than $700 million for the Democratic Party since becoming a party leader in 2002.

Nancy Pelosi was born in Baltimore, Maryland. Pelosi graduated from the Institute of Notre Dame in 1958. She earned a bachelor’s degree from Trinity College in 1962. Pelosi served as the chair of the California State Democratic Party and the finance chairwoman of the Democratic Senatorial Campaign Committee.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.